Bibliography Aapro, M.S. 2001. Adjuvant therapy of primary breast cancer: a review of key findings from the

7th international conference, St. Gallen. Oncologist., 6, 376–385.

Agarwal, C. Tyagi, A. Agarwal, R. 2006. Gallic acid causes inactivating phosphorylation of

cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces

apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther., 5: 3294-302.

Ahmad, A. Mukherhjee, P. Senapati, S. Mandal, D. Khan, M.I. Kumar, R. Sastry, M. 2003.

Extracellular biosynthesis of silver nanoparticles using the fungus Fusarium oxysporum.

Colloids Surf. B., 28: 313-318.

Akita, H. Kudo, A. Minoura, A. Yamaguti, M. Khalil, I.A. Moriguchi, R. 2009. Multi-layered

nanoparticles for penetrating the endosome and nuclear membrane via a step-wise

membrane fusion process. Biomaterials., 30: 2940–2949.

Alexis, F. Pridgen, E. Molnar, L.K. Farokhzad, O.C. 2008. Factors affecting the clearance and

biodistribution of polymeric nanoparticles. Mol. Pharmacol., 5 (4) : 505–515.

Altieri, D.C. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer., 3: 46-

54.

Altieri, D.C. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev

Cancer., 81: 61–70.

Ambrosini, H. Matsuzawa, C. Altieri, D.C. 1997. A novel anti-apoptotic gene, survivin

expressed in cancer and luymphoma. Nat Med., 3: 917-21.

Angell. 2008. A study in to the potential role of survivin localization in resistance to drug-

induced apoptosis. Bioscience Horizons., 1: 2

AshaRani, P.V. Low Kah Mun, G. Hande, M.P. 2009. Valiyaveettil S. Cytotoxicity and

genotoxicity of silver nanoparticles in human cells. ACS Nano., 3: 279-290.

Bibliography Assaraf, Y.G. 2007. Molecular basis of antifolate resistance. Cancer Metast. Rev., 26: 153–181.

Banerjee, R. Tyagi, P. Li, S. Huang, L. 2004. Anisamide-targeted stealth liposomes: a

potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer.,

112: 693–700.

Atobe, K. Ishida, T. Ishida, E. Hashimoto, K. Kobayashi, H. Yasuda, J. Aoki, T. Obata, K.

Kikuchi, H. Akita, H. Asai, T. Harashima, H. Oku, N. Kiwada, H. 2007. In vitro

efficacy of a sterically stabilized immunoliposomes targeted to membrane type1 matrix

metalloproteinase (MT1-MMP). Biol. Pharm. Bull., 30 (5): 972-978.

Avgoustakis, K. 2002. PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle

degradation, in vitro drug release and in vivo drug residence in blood properties. J

Control Release., 791 : 23–35.

Baracca, A. Sgarbi, G. Solaini, G. Lenaz, G. 2003. Rhodamine 123 as a probe of mitochondrial

membrane potential: evaluation of proton flux through F0 during ATP synthesis.

Biochim Biophys Acta.,1606: 137–146.

Bareford, L.M. Swaan, P.W. 2007. Endocytic mechanisms for targeted drug delivery. Adv. Drug.

Deliv. Rev., 59: 748–758.

Barnhart, B.C. Alappat, E.C. Peter, M.E. 2003. The CD95 type I/type II model. Seminors in

Immunology ., 15: 185–193.

Basu, S. Chaudhuri, P. Sengupta, S. 2009. Targeting oncogenic signaling pathways by exploiting

nanotechnology. Cell Cycle., 8: 3480–3487.

Basu, S. Harfouche, R. Soni, S. Chimote, G. Mashelkar, R.A. Sengupta, S. 2009. Nanoparticle-

mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc. Natl

Acad. Sci., 106: 7957-7961.

Bibliography Bhattacharya, R. Mukherjee, P. 2008. Biological properties of “naked” metal nanoparticles.

Advanced Drug Delivery Reviews., 60 : 1289-01306.

Boatright, K.M. Salvesen, G.S. 2003. Mechanisms of caspase activation. Current Opinion in

Cell Biology ., 15: 725–731.

Bodnar, M. Hartmann, J.F. Borbely, J. 2005. Preparation and characterization of chitosan-

based nanoparticles. Biomacromolecules., 6 : 2521–2527.

Bold, R.J. Termuhlen, P.M. McConkey, D.J. 1997. Apoptosis cancer and cancer therapy. Surg

Oncol., 6: 133-142.

Bonneterre, J. Thurlimann, B. Robertson, J.F.R. Krzakowski, M. Mauriac, L. Koralewski, P.

2000. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in

668 postmenopausal women: results of the tamoxifen or arimidex randomized group

efficacy and tolerability study. J Clin Oncol., 18: 3748–3757.

Brid, M. Ryan, Norma O’Donovan. Michael J Duffy. 2009. Survivin: A new target for anti-

cancer therapy. Cancer treatment Review., 12: 84-96.

Brown, S.D. Nativo, P. Smith, J.A. Stirling, D. 2010. Gold nanoparticles for the improved

anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc., 132:

4678–4684.

Broxterman, H.J. Gotink, K.J. Verheul, H.M. 2009. Understanding the causes of multidrug

resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Update.,

12: 114–126.

Bulut, E. Rapid Ozacar, M. 2009. Facile synthesis of silver nanostructure using hydrolyz-able

tannin. Ind Eng Chem Res., 48: 5686-5690.

Bibliography Burz, C. Berinda n-Neagoe, I. Balaces cu, O. Irimie, A. 2009. Apoptosis in cancer: key

molecular signaling pathways and therapy targets. Acta Oncol., 488: 11-21.

Callegari, A. Tonti, D. Chergui, M. 2003. Photochemically grown silver nanoparticles with

wavelength-controlled size and shape. Nano Lett., 3: 1565-1568.

Cameron, D.A. Ritchie, A.A. Langdon, S. Anderson, T.J. Miller, W.R. 1997. Tamoxifen induced

apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer

Res Treat., 45: 99–107.

Carey, L.A. Dees, E.C. Sawyer, L. Gatti, L. Moore, D.T. Collichio, F. 2007. The triple negative

paradox: primary tumor chemo-sensitivity of breast cancer subtypes. Clin. Cancer Res.,

13: 2329–2334.

Cascone, M.G. 2002. Poly(vinyl alcohol) hydrogels as hydrophilic matrices for the release of

lipophilic drugs loaded in PLGA nanoparticles. J. Mat. Sci. Mat., Med.13: 29–32.

Castedo, M. Perfettini, J. L. Roumier, T. Andreau, K. and Kroemer, G. 2004. Cell death by

mitotic catastrophe: A molecular definition. Oncogene., 23: 2825-2837.

Chan, J. 2000. Down- regulation of survivin by antisense oligonucleotides increase apoptosis,

inhibits cytokinesis and anchorage independent growth. Neoplasia., 2: 235-241.

Chau, C.F. Wu, S.H. Yen, G.C. 2007. The development of regulations for food nanotechnology.

Trends Food Sci Tech., 18: 269-280.

Chen, A.M. Zhang, M. Wei, D.G. Stueber, D. Taratula, O. Minko, T. He, H.X. 2009. Co-

delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances

the efficacy of chemotherapy in multidrug-resistant cancer cells. Small., 5: 2673–2677.

Chen, X. Schluesener, H.J.2008. Nanosilver: a nanoproduct in medical application. Toxicol Lett.,

176: 1-12.

Bibliography Cho, K.J. Wang, X. Nie, S.M. Chen, Z. Shin, D.M. 2008. Therapeutic nanoparticles for drug

delivery in cancer. Clin. Cancer. Res., 14: 1310–1316.

Choedon, T. Shukla, S.K. Kumar, V. 2010. Chemopreventive and anti-cancer properties of the

aqueous extract of flowers of Butea monosperma. J Ethnopharmacol., 129: 208-213.

Circu, M.L. Aw, T.Y. 2010. Reactive oxygen species, cellular redox systems, and apoptosis.

Free Radic. Biol.Med., 48: 749-762.

Cleator, S. Heller, W. Coombes, R.C. 2007. Triple-negative breast cancer: therapeutic options.

Lancet Oncol., 8: 235-244.

Cobleigh, M.A. Vogel, C.L. Tripathy, D. Robert, N.J. Scholl, S. Fehrenbacher. L. 1999.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal

antibody in women who have HER2-overexpressing metastatic breast cancer that has

progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639–2648.

Colnaghi, R. Connel, C.M . Barrett, R.M .2006. Sepaerating the anti-apoptotic and mitotic roles

of survivin. J.Biol.Chem., 281: 33450-33456.

Conlin, A.K. Seidman, A.D. Bach, A., et al., 2010. Phase II trial of weekly nanoparticle albumin-

bound paclitaxel with carboplatin and trastuzumab as first-line therapy forwomen with

HER2-overexpressing metastatic breast cancer. Clin. Breast Cancer .,10: 281–287.

Conway, E.M. Zwerts, F. Van Eygen, V. 2003. Survivin-dependent angiogenesis in ischemic

brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol., 1633:

935–946.

Couvreur, P. Vauthier, C. 2006. Nanotechnology: intelligent design to treat complex disease.

Pharm. Res., 23: 1417-1450.

Bibliography Culy, C.R. Clemett, D. Wiseman, L.R. 2000. Oxaliplatin: A review of its pharmacological

properties and clinical efficacy in metastatic colorectal cancer and its potential in other

malignancies. Drugs., 60 : 895-924.

Cuzick, J. Powles, T. Veronesi, U. Forbes, J. Edwards, R. Ashley, S. 2003. Overview of the

main outcomes in breast-cancer prevention trials. Lancet., 361: 296–300.

Dai, Y. Grant, S. 2007. Targeting multiple arms of the apoptotic regulatory machinery. Cancer

Res., 67: 2908–2911.

Debatin, K.M., 2004. Apoptosis pathways in cancer and cancer therapy. Cancer Immunology

Immunotheraphy., 53: 153–159.

Decuzzi, P. Ferrari, M. 2006. The adhesive strength of non-spherical particles mediated by

specific interactions. Biomaterials., 27 : 5307–5314.

Decuzzi, P. Lee, S. Bhushan, B. Ferrari, M. 2005. A theoretical model for the margination of

particles within blood vessels. Ann. Biomed. Eng., 33: 179–190.

Decuzzi, P. Ferrari, M. 2008. Design maps for nanoparticles targeting the diseased

microvasculature . Biomaterials., 29 : 377–384.

Di, A and Paolo. 2004. Liposomal anticancer therapy: pharmacokinetic and clinical aspects. J.

Chemother., 16: 90–93.

Dimitrijevic, N.M. Bartels, D.M. Jonah, C.D. Takahashi, K. Rajh, T. 2001. Radiolytically

induced formation and optical absorption spectra of colloidal silver nanoparticles in

supercritical ethane. J Phys Chem B., 105: 954-959.

Dubas, S.T. Pimpan, V. 2008. Humic acid assisted synthesis of silver nanoparticles and its

application to herbicide detection. Mater Lett., 62: 2661-2663.

Bibliography Duffy, M.J. O’Donovan N, Brennan D.J. Gallagher W.M. Ryan, B.M. 2007. Survivin: a

promising tumor biomarker. Cancer Lett., 2491: 49–60.

Earnshaw, W.C. 2005. Cell biology keeping survivin nimble at centromers in mitosis. Science.,

310: 1443-1444.

Endoh, A. Asanuma, K. Moriai, R. Yamada, M. Koyanagi, Y. Sato, T. 2001. Expression of

survivin mRNA in CD4+ cells. Clin. Chim.Acta., 306: 149-151.

Farokhzad, O.C. Karp, J.M. Langer, R. 2006. Nanoparticle-aptamer bio-conjugates for cancer

targeting Expert Opin. Drug Deliv., 3: 311–324.

Fawell, S. Seery, J. Daikh, Y. Moore, C. Chen, L.L. Pepinsky, B. Barsoum, J. 1994. Tat-

mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A., 91:

664–668.

Fendly, B.M. Winget, M. Hudziak, R.M. Lipari, M.T. Napier, M.A. Ullrich, A. 1990.

Characterization of murine monoclonal antibodies reactive to either the human epidermal

growth factor receptor or HER2/neu gene product Cancer. Res., 50: 1550–1558.

Feng, S.S. Mu, L. Win, K.Y. Huang, G. 2004. Nanoparticles of biodegradable polymers for

clinical administration of paclitaxel. Curr. Med. Chem., 11: 413.

Fengzhi Li and Xiang Ling .2006. Survivin study: An update of “What is the Next Wave”.

J.Cell. Physio., 208: 476-86.

Ferrari, M. 2005. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer., 5:

161–171.

Ferrari, M. 2005. Nanovector therapeutics. Curr. Opin. Chem. Biol., 9: 343-346.

Ferrari, M. 2008. Beyond drug delivery. Nat. Nanotechnol., 3; 131–132.

Bibliography Fesik, S.W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer.,

511: 876–85.

Fessi, H. Puisieux, F. Ph. Devissaguet, J. Ammoury, N. Benita, S. 1989. Nanocapsule formation

by interfacial polymer deposition following solvent displacement. Int. J. Pharm., 55

(1):1–4.

Fisher, B. Costantino, J.P. Wickerham, D.L. Cecchini, R.S. Cronin, W.M. Robidoux, A. 2005.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical

Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst., 97: 1652–1662.

Fornari, F.A. Randolph, J.K. Yalowich, J.C. Ritke, M.K. Gewirtz, D.A. Interference by

doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol., 45:

649–656 (1994).

Fujie, Y. Yamamoto, H. Ngan, C.Y. Takagi, A. Hayashi, T. Suzuki, R. Ezumi, K. Takemasa,

I. Ikeda, M. Sekimoto, M. Matsuura, N. Monden, M. 2005. Oxaliplatin, a Potent

Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in

Colon Cancer Cells. Jpn J Clin Oncol., 35: 453-463.

Fujie, Y. Hirofumi Yamamoto, Chew Yee Ngan, Akimitsu Takagi, Taro Hayashi, Rei Suzuki,

Koji Ezumi, Ichiro Takemasa, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsuura and

Morito Monden. 2005. Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-

induced Apoptosis and Mitotic Catastrophe in Colon Cancer Cells. Jpn J Clin Oncol

.,35(8)4: 53–463.

Gabizon, A. Shmeeda, H. Horowitz, A.T. Zalipsky, S. 2004. Tumor cell targeting of liposome-

entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv.Drug Deliv.

Rev., 56:1177-1192.

Bibliography Garrec , L.D. Gori, S. Luo, L. Lessard, D. Smith, D.C. Yessine, M.A. Ranger, M. Leroux,

J.C. 2004. Poly (N-vinylpyrrolidone)-block-poly(D, L-lactide) as a new polymeric

solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J. Control.

Release., 99 (1) : 83–101.

Gentile, F. Ferrari, M. Decuzzi, P. 2008. The transport of nanoparticles in blood vessels: the

effect of vessel permeability and blood rheology. Ann. Biomed. Eng., 36: 254–261.

Ghavami, S. Hashemi, M. Ande, S.R. 2009. Apoptosis and cancer: mutations within caspase

genes. J Med Genet., 46(8): 497–510.

Gibb, R.K. Taylor, D.D. Wan, T. O’Connor, D.M. Doering, D.L. Taylor, C.G. 1997. Apoptosis

as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell

lines. Gynecol Oncol., 65: 13-22.

Giodini, A. Kallio, M.J. Wall, N.R. 2002. Regulation of microtubule stability and mitotic

progression by survivin. Cancer Res., 62: 2462-2467.

Green, D.R. Kroemer, G. 2004. The pathophysiology of mitochondrial cell death. Science., 305:

626-629.

Green, J.J. Chiu, E. Leshchiner, E.S. Shi, J. Langer, R. Anderson, D.G. 2007. Electrostatic

ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary

cells. Nano Lett., 7: 874–879.

Green, S. Walter, P. Kumar, V. Krust, A. Bornert, J.M. Argos, P. 1986. Human oestrogen

receptor cDNA: sequence, expression and homology. Nature., 320: 134-139.

Hanahan, D and Weinberg, R.A. 2011. Hallmarks of Cancer: The Next Generation. Cell., 144:

646-674.

Bibliography Henneke, P. Golenbock, D.T. 2004. Phagocytosis, innate immunity, and host-pathogen

specificity. J. Exp. Med., 199: 1–4.

Henry, S.M. El-Sayed, M.E. Pirie, C.M. Hoffman, A.S. Stayton, P.S. 2006. pH-responsive

poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery.

Biomacromolecules ., 7: 2407–2414.

Hsin, Y.H. Chen, C.F. Huang, S. Shih, T.S, Lai, P.S. Chueh, P.J. 2008. The apoptotic effect of

nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the

mitochondrial pathway in NIH3T3 cells. Toxicol Lett., 179: 130-139.

Hu, C.M. Zhang, L.F. 2009. Therapeutic nanoparticles to combat cancer drug resistance. Curr.

Drug Metab., 10: 836–841.

Hu, R. Yong, K.T. Roy, I. Ding, H. He, S. Prasad, P.N. 2009. Metallic nanostructures as

localized Plasmon resonance enhanced scattering probes for multiplex dark field targeted

imaging of cancer cells. J Phys Chem C: Nanomater Interfaces., 113: 2676-84.

Huang, S.T. Yang, R.C. Lee, P.N. Yang, S.H. Liao, S.K. Chen, T.Y. 2006. Anti-tumor and anti

angiogenic effects of Phyllanthus urinaria in mice bearing Lewis lung carcinoma. Int

Immunopharmacol .,6: 870–879.

Hussain, S. M. Hess, K. L. Gearhart, J. M. Geiss, K. T. and Schlager, J. J. 2005. In vitro toxicity

of nanoparticles in BRL-3A rat liver cells. Toxicol. In Vitro., 19: 975-983.

J.M. Elwood, B. Cox, A.K. Richardson. 1993. The effectiveness of breast cancer screening by

mammography in younger women. J. Curr. Clin. Trials., 32.

Jain, A. Jain, S.K. Ganesh, N. Barve, J. Beg, A.M. 2010. Design and development of ligand-

appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal

cancer. Nanomedicine., 6: 179-190.

Bibliography Jayshree, P.D. Vipin, K. 2008. Annona squamosa L. Phytochemical analysis and Antimicrobial

Screening. J of Phar Res., 1: 34-38.

Jemal, A. Siegel, R. Ward, E. Murray,T. Xu, J. Thun, M J. 2007. Cancer statistics. CA Cancer

J. Clin., 57: 43–66.

Joerger, K.T. Joerger, R. Olsson, E. Granqvist, C.G. 2001. Bacteria as workers in the living

factory: metal-accumulating bacteria and their potential for materials science. Trends

Biotechnol ., 19: 15–20.

Juan, B.H. Zhang, Z.M. Gong, J. 2006. Biological synthesis of semiconductor zinc sulfide

nanoparticles by immobilized Rhodobacter sphaeroides. Biotechnol Lett., 28: 1135–

1139.

Kaitna, S. Mendosa, M. Jantch-Plunger, V. and Glotar, M. 2000. INCENP and Aurora like

kinase form a complex essential for chromosome segregation and efficient completion of

cytokinesis. Curr Biol., 10:1072-1081.

Kalimuthu, K. Babu, R.S. Venkataraman, D. Bilal, M. Gurunathan, S. 2008. Biosynthesis of

silver nanocrystals byBacillus licheniformis. Colloids Surf B., 65: 150–153.

Kam, N.W. O'Connell, M. Wisdom, J.A. Dai, H. 2005. Carbon nanotubes as multifunctional

biological transporters and near-infrared agents for selective cancer cell destruction.

Proc. Natl. Acad. Sci., 102: 11600–11605.

Kamada, H. Tsutsumi, Y. Yamamoto, Y. Kihira, T. Kaneda, Y. Mu, Y. Kodaira, H. Tsunoda, S.

Nakagawa, S. Mayumi, T. 2000. Antitumor activity of tumor necrosis factor-alpha

conjugated with polyvinylpyrrolid one on solid tumors in mice. Cancer Res., 60 (22):

6416– 6420.

Bibliography Kaneda, Y. Tsutsumi, Y. Yoshioka, Y. Kamada, H. Yamamoto, Y. Kodaira ,H. 2004. The use of

PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials., 25:

3259-66.

Karon, M. Weissman, S. Meyer, C. Henry, P. 1965. Studies of DNA, RNA, and Protein

Synthesis in Cultured Human Cells Exposed to 8-Azaguanine. Cancer Res., 25: 185-192.

Kathiresan, K. Manivannan, S. Nabeel, M.A. Dhivya, B. 2009. Studies on silver nanoparticles

synthesized by a marine fungus, Penicillium fellutanum isolated from coastal mangrove

sediment. Colloids Surf B Biointerfaces., 71:133–137.

Kawada, M. Ohno, Y. Ri, Y. Ikoma, T. Yuugetu, H. Asai, T. 2001. Anti-tumor effect of gallic

acid on LL-2 lung cancer cells transplanted in mice. Anticancer Drugs., 12: 847-852.

Kerlikowske, K. 1997. Efficacy of screening mammography among women aged 40 to 49 years

and 50 to 69 years: comparison of relative and absolute benefit. J. Natl. Cancer Inst.

Monogr., 22: 79–86.

Kiemer, A.K. Hartung, T. Huber, C. 2003. Vollmar AM. Phyllanthus amarus has anti-

inflammatory potential by inhibition of iNOS COX-2, and cytokines via NF-kB pathway.

J Hepatol ., 38(3): 289–97.

Kim, D. Lee, E.S. Oh, K.T. Gao, Z.G. Bae, Y.H. 2008. Doxorubicin-loaded polymeric micelle

overcomes multidrug resistance of cancer by double-targeting folate receptor and early

endosomal pH. Small., 4: 2043–2050.

Kim, R. Tanabe, K. Uchida, Y. Emi, M. Inoue, H. Toge, T. 2002. Current status of the molecular

mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level

analysis to cancer chemotherapy. Cancer Chemotheraphy and Pharmacology., 50: 343–

352.

Bibliography Kim, S.W. Han, Y.W. Lee, S.T. Jeong, H.J. Kim, S.H. Kim, I.H.l. 2008. A superoxide anion

generator, pyrogallol, inhibits the growth of HeLa cells via cell cycle arrest and

apoptosis. Mol Carcinogen., 47: 114-25.

Kinnane, C.R. Such, G.K. Antequera-Ga rcía, G. Yan, Y. Dodds, S.J. Liz-Marzan, L.M.

Caruso, F. 2009. Low-fouling poly(N-vinyl pyrrolidone) capsules with engineered de-

gradable properties. Biom acromolecules ., 10 : 2839 – 2846.

Kirkin, V. Joos, S. Zornig. M. 2004. The role of Bcl-2 family members in tumorigenesis.

Biochim Biophys Acta., 1644: 229-249.

Kisak, E.T. Coldren, B. Evans, C.A. Boyer, C. Zasadzinski, J.A. 2004. The vesosome-a

multicompartment drug delivery vehicle. Curr. Med. Chem., 11:199-219.

Kleihues, P. Ohgaki, H. 2000. Phenotype vs genotype in the evolution of astrocytic brain

tumors. Toxicol Pathol., 28:164-170.

Kleihues, P. Louis, D.N. Scheithauer, B.W. Rorke, L.B. Eifenberger, G. Burger, P.C.

Cavenee, W.K. 2002. The WHO classification of tumors of the nervous system. J.

Neuropathol. Exp. Neurol., 61: 215-225.

Kobayashi, T. Ishida, T. Okada, Y. Ise, S. Harashima, H. Kiwada, H. 2007. Effect of

transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug

resistant tumor cells. Int. J. Pharm., 329 (1-2): 94-102.

Kockisch, S. Rees, G.D. Young, S.A. Tsibouklis, J. Smart, J.D. 2005. Mucoadhesive, triclosan-

loaded polymer microspheres for application to the oral cavity: preparation and

controlled release characteristics. Eur. J. Pharm. Biopharm., 59: 207-216.

Bibliography Konecny, G. Pauletti, G. Pegram, M. Untch, M. Dandekar, S. Aguilar, Z. 2003. Quantitative

association between HER-2/neu and steroid hormone receptors in hormone receptor-

positive primary breast cancer. J. Natl. Cancer Inst., 95:142–153.

Koppler, M. Taubert, H. Bertel, F. Blumke, K. Panjan, M. Schmidt, H. Bache, M. 2005. Radio

sensitization, after a combined treatment of survivin by siRNA and irradiation is

correlated of pancreatic cancer caspase 3 and 7 in a wt-p53 sarcoma cell line, but not in a

mt-p53 sarcoma cell line. Oncol Rep., 13: 167-172.

Kowshik, M. Vogel, W. Urban, J. Kulkarni, S.K. Paknikar, K.M. 2002. Microbial synthesis of

semiconductor PbS nano-crystallites. Adv Mater., 14: 815–818.

Kumar, N. 1981. Taxol-induced polymerization of purified tubulin. Mech-anism of action. J.

Biol. Chem., 256: 10435–10441.

Kumar, S. Harrison, N. Richards-Kortum, R. Sokolov, K. 2007. Plasmonic nanosensors for

imaging intracellular biomarkers in live cells. Nano Lett., 7: 1338–1343.

Kumar, V. Green, S. Stack, G. Berry, M. Jin, J.R. Chambon, P. 1987. Functional domains of

the human estrogen receptor. Cell., 51: 941–951.

Kumar, V. Green, V.S. Staub, A. Chambon, P. 1986. Localisation of the oestradiol-binding and

putative DNA-binding domains of the human oestrogen receptor. EMBO J., 5: 2231-

2236.

Lampson, M.A. Renduchitala, K. Khodhakuv, A. Kapoor, T.M. 2004. Correcting improper

chromosome-spindle attachment during cell division. Nat Cell Biology., 798-812.

Lee, E.S. Gao, Z.G. Kim, D. Park, K. Kwon, I.C. Bae, Y.H. 2008. Super pH-sensitive

multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug

resistance. J. Control. Release., 129: 228–236.

Bibliography Lee, M.K. Chun, S.K. Choi, W.J. Kim, J.K. Choi, S.H. Kim, A. Oungbho, K. Park, J.S. Ahn,

W.S. Kim, S.K. 2005. The use of chitosan as a condensing agent to enhance emulsion-

mediated gene transfer. Biomaterials., 26: 2147-2156.

Levin E.R. 2009. Plasma membrane estrogen receptors. Trends in Endocrinology and

Metabolism ., 20 (10): 477-482.

Li and Xiang Ling. 2006. Survivin study: An update of “What is the Next Wave”. J.Cell.

Physiol., 208: 476-86.

Li F. 2003.Survivin study: what is the next wave? J Cell Physiol.,1971: 8–29.

Liebmann, J. Cook, J.A. Mitchell, J.B. Cremophor, E.L. 1993. Solvent for paclitaxel, and

toxicity. Lancet., 342: 1428.

Liu, T. Brouha, B. Grossman, D. 2004. Rapid induction of mitochondrial events and caspase-

independent apoptosis in survivin targeted melanoma cells. Oncogene., 23: 39-48.

Logue, S.E. Martin, S.J. 2008. Caspase activation cascades in apoptosis. Biochem Soc Trans.,

36: 1-9.

Loo, C. Lowery,A. Halas, N. West, J. Drezek, R. 2005. Immunotargeted nanoshells for

integrated cancer imaging and therapy. Nano Lett., 5: 709–711.

Lopergolo, L.C. Lugao, A.B. Catalani, L.H. 2003. Direct UV photocrosslinking of poly (N-

vinyl-2-pyrrolidone) (PVP) to produce hydrogels. Polymer .,44: 6217-6222.

Lu, D. Wientjes, M.G. Lu, Z. Au, J.L. 2007. Tumor priming enhances delivery and efficacy of

nanomedicines. J Pharmacol Exp Ther., 322: 80–88.

Lukyanov, A.N . Torchilin, V.P. 2004. Micelles from lipid derivatives of water-soluble polymers

as delivery systems for poorly soluble drugs. Adv. Drug Deliv. Rev., 56 (9): 1273-1289.

Bibliography Luo, L.B. Ranger, M. Lessard, D.G. Le Garrec, D. Gori, S. Leroux, J.C. Rimmer, S. Smith, D.

2004. Novel amphiphilic diblock copolymer of low molecular weight poly(N-

vinylpyrrolidone)-block-poly(D, L-lactide): synthesis, characterization, and micellization.

Macromolecules., 37 (11) : 4008–4013.

Ly, J.D. Grubb, D.R. Lawen, A. 2003. The mitochondrial membrane potential (deltapsi(m)) in

apoptosis; an update. Apoptosis., 8: 115–128.

Maeda, H. Fang, J. Inutsuka, T. Kitamoto, Y. 2003. Vascular permeability enhancement in solid

tumor: various factors, mechanisms involved and its implications. Int.

Immunopharmacol., 3: 319–328.

Maeda, H. Seymore, L.W. Miyamoto, Y. 1992. Conjugates of anticancer agents and polymers:

advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry., 3: 351-

162.

Mao, S. Sun, W. Kissel, T. 2010. Chitosan-based formulations for delivery of DNA and siRNA.

Advanced Drug Delivery Reviews., 62:12-27.

Marambio-Jones, C. Hoek, E.M.V. 2010. The antibacterial effects of silver nanomaterials and

potential implications for human health and the environment. J Nanopart Res., 12:1531–

1551.

Missirlis, D. 2005. Amphiphilic hydrogel nanoparticles. Preparation, characterization, and

preliminary assessment as new colloidal drug carriers. Langmuir., 21: 2605–2613.

Miura, N. Shinohara, Y. 2009. Cytotoxic effect and apoptosis induction by silver nanoparticles in

HeLa cells. Biochemical and Biophysical Research Communications .,390: 733-737.

Bibliography Mo, Y. Lim, L.Y. 2005. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer

activity by surface conjugation with wheat germ agglutinin. J Control Release., 108:

244–62.

Mo, Y. Lim, L.Y. 2005. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer

activity by surface conjugation with wheat germ agglutinin. J Control Release., 108:

244-262.

Mohamed, T. El-Ghamry. Roland, W.F. 1968. Spectrophotometric Determination of Trace

Amounts of Silver. Anal Chem., 40: 1986-1990.

Mu, L. Feng, S.S. 2003. A novel controlled release formulation for the anticancer drug Paclitaxel

(Taxol): PLGA nanoparticles containing vitamin E. TPGS, J. Control. Release., 86: 33–

48.

Naik, R.R. Stringer, S.J. Agarwal, G. Jones, S.E. Stone, M.O. 2002. Biomimetic synthesis and

patterning of silver nanoparticles. Nat Mater., 1: 169-72.

Narayanan, K.B. Sakthivel, N. 2010. Biological synthesis of metal nanoparticles by microbes.

Adv Colloid Interface Sci., 156:1–13.

Naugler, W.E. Karin, M. 2008. NF-kappaB and cancer- identifying targets and mechanisms.

Curr Opin Genet Dev., 18: 19-26.

Nel, A. E. Madler, L. Velegol, D. Xia, T. Hoek, E. M. Somasundaran, P. Klaessig, F.

Castranova, V. Thompson, M. 2009. Understanding Biophysicochemical Interactions at

the Nano-Bio Interface. Nat. Mater., 8: 543–557.

Ni, C.D. Ma, Y.D. 2006. Immunohistochemistry experiment technology and application.

Chemical Industry Publishing Company, Beijing., 86.

Bibliography Nicolis, E. Lampronti, I. Dechecchi, M.C. Borgatti, M. Tamanini, A. Bianchi, N. Bezzerri, V.

Mancini, I. Giri, M.G. Rizzotti, P. Gambari, R. Cabrini, G. 2008. Pyrogallol, an active

compound from the medicinal plant Emblica of ficinalis, regulates expression of

proinflammatory genes in bronchial epithelial cells. International

Immunopharmacology., 8: 1672-1680.

Nihal, M. Ahmad, N. Mukhtar, H. Wood, G.S. 2005. Anti-proliferative and proapoptotic effects

of ()-epigallocatechin-3-gallate on human melanoma: possible implications for the

chemoprevention of melanoma. International Journal of Cancer., 114: 513–521.

Ntalli, N.G. Cottiglia, F. Bueno, C.A. Alche, L.E. Leonti, M. Vargiu, S. 2010. Cytotoxic

Tirucallane Triterpenoids from Melia azedarach fruits. Molecules., 15: 5866-5877.

Nyman, D.W. Campbell, K.J. Hersh, E. Long, K. Richardson, K. Trieu. V. et al., 2005. Phase I

and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in

patients with advanced nonhematologic malignancies. J. Clin. Oncol., 23: 7785–7793.

O’Connor, D.S. Schechner, J.S. Adida, C. 2000. Control of apoptosis during angiogenesis by

survivin expression in endothelial cells. Am J Pathol., 1562: 393–398.

O’Regan, R.M. Jordan, V.C. 2002. The evolution of tamoxifen therapy in breast cancer: selective

oestrogen-receptor modulators and downregulators. Lancet Oncol., 3: 207–214.

Ohno, Y. Fukuda, K. Takemura, G. Toyota, M. Watanabe, M. Yasuda, N. 1999. Induction of

apoptosis by gallic acid in lung cancer cells. Anticancer Drugs., 10: 845-851.

Oltvai, Z.N. Milliman, C.L. Korsmeyer, S.J. 1993. Bcl-2 heterodimerizes in vivo with a

conserved homolog, Bax, that accelerates programmed cell death. Cell., 74: 609–619.

Osborne, C.K. 1998. Drug therapy-Tamoxifen in the treatment of breast cancer. N Engl J Med.,

339:1609-1618.

Bibliography Paleos, C.M. Tsiourvas, D. Sideratou, Z. Tziveleka, L. Acid- and salt-triggered multifunctional

poly(propylene imine) dendrimer as a prospective drug delivery system,

Biomacromolecules ., 5 : 524-529.

Pan, B. Cui, D. Sheng,Y. Ozkan, C. Gao, F. He, R. et al., 2007. Dendrimer-Modified Magnetic

anoparticles Enhance Efficiency of Gene Delivery System Cancer. Res., 67: 8156–8163.

Paoluzzi, L. O’Connor, O.A. 2010. Targeting survival pathways in lymphoma. Adv. Exp. Med.

Biol., 687: 79–96.

Park, W.H. Han, Y.W. Kim, S.H. Kim, S.Z. 2007. A superoxide anion generator, Pyrogallol

induces apoptosis in As4.1 cells through the depletion of intracellular GSH content.

Mutat Res., 619: 81-92.

Parkin, D.M. 2001. Global cancer statistics in the year 2000. Lancet Oncol., 2: 533–543.

Parveen, S. Sahoo, S.K. 2008. Polymeric nanoparticles for cancer therapy. J. Drug Target., 16:

108–123.

Pedram, A. Razandi, M. Levin, E.R. 2006. Nature of functional estrogen receptors at the plasma

membrane. Mol. Endocrinol., 20 (9): 1996–2009.

Peng, J. He, X. Wang, K. Tan, W. Li, H. Xing, X. 2006. An antisense oligonucleotide carrier

based on amino silica nanoparticles for antisense inhibition of cancer cells.

Nanomedicine., 2:113–120.

Pennati, M. Folini. M. Zaffaroni, N. 2007. Targeting survivin in cancer therapy: fulfilled

promises and open questions. Carcinogenesis., 286:1133–1139.

Pinhassi, R.I. Assaraf, Y.G. Farber, S. Stark, M. Ickowicz, D. Drori, S. Domb, A.J. Livney, Y.D.

2010. Arabinogalactan-folate-drug conjugate for targeted delivery and target-activated

Bibliography

release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules.,

11: 294–303.

Pound, G. McKenzie, J.M. Lange, R.F.M. Klumperman, B. 2008. Polymer–protein conjugates

from aldehyde endfunctional poly (N-vinylpyrrolidone) synthesised via xanthate-

mediated living radical polymerization. Chem. Commun., 27: 3193 –3195.

Qi, F. Li, A. Zhao, L. Xu, H. Inagaki, Y. Wang, D. 2010. Cinobufacini, an aqueous extract from

Bufobufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated

pathway in human hepato cellular carcinoma cells. J Ethnopharmacol., 128: 654-661.

Qiao, L. Wong, B.C. 2009. Targeting apoptosis as an approach for gastrointestinal cancer

therapy. Drug Resist. Update., 12: 55-64.

Radhika, N.K. Sreejith, P.S. Asha, V.V. 2010. Cytotoxic and apoptotic activity of Cheilanthes

farinose (Forsk.) Kaulf. Against human hepatoma, Hep3B cells. J Ethnopharmacol.,

128: 166-171.

Rajkapoor, B. Sankari, M. Sumithra, M. Anbu, J. Harikirishnan, N. Gobinath, M. 2007.

Antitumor and cytotoxic effects of Phyllanthus polyphyllus on ehrlich ascites carcinoma

and human cancer cell lines. Biosci Biotechnol Biochem., 71(9): 2177–2183.

Rao, G.S. 1981. Mode of entry of steroid and thyroid hormones into cells. Mol. Cell.

Endocrinol., 21: 97–108.

Ravdin, P.M. Green, S. Dorr, T.M. McGuire, W.L. Fabian, C. Pugh, R.P. 1992. Prognostic-

significance of progesterone-receptor levels in estrogen receptor-positive patients with

metastatic breast-cancer treated with tamoxifen-results of a prospective Southwest-

Oncology-Group Study. J Clin Oncol., 10:1284–91.

Bibliography Raveendran, P. Fu, J. Wallen, S.L. 2003. Completely "green" synthesis and stabilization of metal

nanoparticles. J Am Chem Soc.,125 (46):13940-13951.

Raymond, E. Faivre, S. Chaney, S. Woynarowski, J.M. 2002. Cellular and molecular

pharmacology of Oxaliplatin. Mol Cancer Ther., 1 : 227–235.

Reed, J.C. 2003. Apoptosis-targeted therapies for cancer. Cancer Cell., 3: 17.

Reents, R. Jeyaraj, D.A. Waldmann, H. R. 2002. Enzymatically cleavable linker groups in

polymer-supported synthesis. Drug Discov., Today 7: 71-76.

Reiko, H. Ronan, K. Erich, A.N. 2003. Exploring the functional interaction between Aurora B,

INCEP and survivin in mitosis. Mol. Cell. Biol., 23: 3325-3341.

Resnick, T. D. 2006. INCEP and Aurora B promote in meiotic sister chromatid cohesion through

localization of the shugoshin ME1-S332 drosophila. Dev.Cell., 11: 57-68.

Rivera, E. 2003. Liposomal anthracyclines in metastatic breast cancer: clinical update

Oncologist 8: 3-9.

Robey, R.W. Shukla, S. Finley, E.M. Oldham, R.K. 2008. Inhibition of P-glycoprotein

(ABCB1)- and multidrug resistance-associated protein 1(ABCC1)-mediated transport by

the orally administered inhibitor, CBT-1®. Biochem. Pharmacol., 75: 1302–1312.

Robidoux, A. Buzdar, A.U. Quinaux, E. Jacobs, S. Rastogi, P. 2010. A phase II neo adjuvant

trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-

fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin. Breast

Cancer., 10: 81-86.

Rosa, J. Canovas, P. Islam, A. Altieri, D.C. Doxsey, S.J. 2006. Survivin modulates

microtubule dynamics and nucleation throughout the cell cycle. Mol. Biol. Cell., 17:

1483–1493.

Bibliography Rouf, M.A. Vural, I. Renoir, J.M. Hincal, A.A. 2009. Development and characterization of

liposomal formulations for rapamycin delivery and investigation of their antiproliferative

effect on MCF7 cells. J. Liposome Res., 19: 322–331.

Ruchaud, S. Carmena, M. Earnshaw, W.C. 2007. Chromosomal passengers: conducting cell

division. Nat. Rev. Mol. Cell Biol., 8: 798–812.

Rudolph, C. Plank, C. Lausier, J. Schillinger, U. Müller, R.H. Rosenecker, J. 2003. Oligomers of

the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid

DNA into cells. J. Biol. Chem., 278: 11411–11418.

Ryan, B.M, Norma, O’Donovan, Michael, J. Duffy. 2009. Survivin: A new target for anti-cancer

therapy. Cancer Treatment Reviews 35: 553-562.

Saeki, K. Hayakawa, S. Isemura, M. Miyase, T. 2000. Importance of a pyrogallol-type structure

in catechin compounds for apoptosis-inducing activity. Phytochemistry., 53: 391-394.

Salem, A.K. Searson, P.C. Leong, K.W. 2003. Multifunctional nanorods for gene delivery, Nat.

Mater., 2: 668-671.

Sampath, S.C. Ohi, R. Leismann, O. Salic, A. Pozniakovski, A. Funabiki, H. 2004. The

chromosomal passenger complex is required for chromatin-induced microtubule

stabilization and spindle assembly. Cell., 118 :187-202.

Sanchez-Lamaz, A. Fiore, M. Cundari, E. Rocordy, R. Cozzi, R. De Salvia, R. 1999. Phyllanthus

orbicularis aqueous extracts: cytotoxic, genotoxic, and antimutagenic effects in the CHO

cell line. Toxicol Appl Pharmacol., 161: 231-239.

Sandall, S. Severin, F. McLeod, I.X. Yates, J.R. Oegema, K. Hyman, A. Desai, A. 2006. A

Bir1–Sli15 complex connects centromeres to microtubules and is required to sense

kinetochore tension. Cell., 127: 1179-1191.

Bibliography Sanhai, W.R. Sakamoto, J.H. Canady, R. Ferrari, M. 2008. Seven challenges for nanomedicine.

Nat. Nanotechnol., 3: 242–244.

Sathishkumar, M. Sneha, K. Won, S.W. Cho, C.W. Kim, S. Yun, Y.S. 2009. Cinnamon

zeylanicum bark extract and powder mediated green synthesis of nanocrystalline silver

particles and its bactericidal activity. Colloids Surf. B: Bioint., 73: 332-338.

Schleicher, S.M., Moretti, L., Varki, V., Lu, B. 2010. Progress in the unraveling of the

endoplasmic reticulum stress/autophagy pathway and cancer: implications for future

therapeutic approaches. Drug Resist. Update., 13, 79–86.

Schoenmakers, R.G. 2004. The effect of the linker on the hydrolysis rate of drug-linked ester

bonds. J. Control. Release., 95:291-300.

Schultz, D.R. Harrington, W.J. 2003. Apoptosis: programmed cell death at a molecular level

Semin. Arthritis Rheum., 32: 345-369.

Sengupta, S. Eavarone, D. Capila, I. Zhao, G.L. Watson, N. Kiziltepe, T. 2005. Temporal

targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature.

436: 568-572.

Sengupta, S. Tyagi, P. Velpandian, T. Gupta, Y.K. Gupta, S.K. 2000. Etoposide encapsulated in

positively charged liposomes: pharmacokinetic studies in mice and formulation stability

studies. Pharmacol Res., 424: 59-64.

Sethi, G. Sung, B. Aggarwal, B.B. 2008. Nuclear factor-kappaB activation: from bench to

bedside. Exp Biol Med., 233: 21-31.

Sha, N. K. Khan, G. J. Bisen, P. S. 2006. Structural, functional and therapeutic biology of

survivin. Cancer Letters., 244:164-171.

Bibliography Shafi, G. Munshi, A. Hasan, T.N. 2009. Induction of apoptosis in HeLa cells by chloroform

fraction of seed extracts of Nigella sativa. Cancer Cell Int., 9: 29.

Shenoy, D.B. Amiji, M.M. 2005. Poly (ethyleneoxide)-modified poly (epsilon-caprolactone)

nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm., 293: 261-

270.

Shi, Y. 2002. Mechanisms of caspase activation and inhibition during apoptosis. Molecular

Cell., 9: 459-470.

Shi, Y.A. 2001. A structural view of mitochondria-mediated apoptosis. Nat. Struct. Biol., 8:

394-401.

Singh, M. Singh, O. Talwar, G.P. 1995. Biodegradable delivery system for a birth control

vaccine: immunogenicity studies in rats and monkeys. Pharm Res., 12(11):1796-800.

Slamon, D.J. Clark, G.M. Wong, S.G. Levin, W.J. Ullrich, A. McGuire, W.L. 1987. Human

breast cancer: correlation of relapse and survival with amplification of the HER-2/neu

oncogene. Science., 235: 177–182 .

Slamon, D.J. Godolphin, W. Jones, L.A. Holt, J.A. Wong, S.G. Keith, D.E. 1989. Studies of

the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science., 244: 707–

712.

Slamon, D.J. Leyland-Jones, B. Shak, S. Fuchs, H. Paton, V. Bajamonde, A. 2001. Use of

chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that

over-expresses HER2 N. Engl. J. Med., 344: 783–792 .

Snyder, E.L. Saenz, C.C. Denicourt, C. Meade, B.R. Cui, X.S. Kaplan. I. M. 2005. Enhanced

targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by

transducible anticancer peptides. Cancer Res., 65: 10646–10650.

Bibliography Song, M. Wang, X.M. Li, J.Y. Zhang, R.Y. Chen, B.A. Fu, D.G. 2008. Effect of surface

chemistry modification of functional gold nanoparticles on the drug accumulation of

cancer cells. J. Biomed. Mater. Res., 86: 942-946.

Song,M. Guo, D.D. Pan, C. Jiang, H. Chen, C. Zhang, R.Y. Gu, Z.Z. Wang, X.M. 2008. The

application of poly (N-isopropylacrylamide)-co-polystyrene nanofibers as an additive

agent to facilitate the cellular uptake of an anticancer drug. Nanotechnology.,19.

Sood, P. Thurmond, K.B. Jacob, J.E. Waller, L.K. Silva, G.O. Stewart, D,R. Nowotnik, D.P.

2006. Synthesis and characterization of AP5346, a novel polymer-linked

diaminocyclohexyl platinum chemotherapeutic agent. Bioconjug Chem., 171: 270–279.

Sreekumaran, A.N. Tom, R.T. Rajeev Kumar, V.R. Subramaniam, C. Pradeep, T. 2007.

Chemical interactions at noble metal nanoparticle surfaces-catalysis, sensors and devices.

Cosmos., 3: 103-124.

Steinhauser, I. Spankuch, B Strebhardt, K. Langer, K. 2006. Trastuzumab-modified

nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials., 27:

4975–4983.

Sukirtha, R. Priyanka, K. Antony, J.J. Kamalakkannan, S. Thangam, R. Gunasekaran, P.

Krishnan, M. Achiraman, S. 2012. Cytotoxic effect of Green synthesized silver

nanoparticles using Melia azedarach against in vitro HeLa cell lines and lymphoma mice

model. Pro Biochem., 47: 273-279.

Sun, L. Wang, L. Yonghai Song. Guo, C. Sun, Y. Peng, C. 2008. Aggregation-based growth of

silver nanowires at room temperature. App Surf Sci., 254: 2581-2587.

Bibliography Susa, M. Iyer, A.K. Ryu, K. Hornicek, F.J. Mankin, H. Amiji, M.M. Duan, Z.F. 2009.

Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug

resistance in osteosarcoma. BMC Cancer., 9: 399.

Susanne, M.A. Lens, Gerben Vader and Rene, H. Medema. 2006. The case of survivin as mitotic

regulator. Current openion in Cell Biology, 18: 616-622.

Suzuki, A. Ito, T. Hayashida, M. 2000. Survivin initiates procaspase3/p21 complex formation as

a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene., 19 : 1346-

1353.

Szakacs, G. Paterson, J.K. Ludwig, J.A. Booth-Genthe, C. Gottesman, M.M. 2006. Targeting

multidrug resistance in cancer. Nat. Rev. Drug Discov., 5: 219-234.

Takakura, Y. Hashida, M. 1995. Macromolecular drug carrier systems in cancer che-motherapy:

macromolecular prodrugs. Critical Reviews in Oncology/Hema-tology., 18: 207–31.

Tasciotti, E. Liu, X.W. Bhavane, R. Plant, K. Leonard, A.D. Price, B.K. 2008. Mesoporous

silicon particles as a multistage delivery system for imaging and therapeutic applications.

Nat. Nano-technol., 3: 151–157.

Thei, T. Peter, D. Eric Drexler, J.K. 2006. Nanotechnology. Nat. Nanotechnol., 1:8–10.

Todd, R.C. Lippard, S.J. 2009. Inhibition of transcription by platinum antitumor compounds.

Metallomics 1(4):280-291.

Torresdey, J.L. Parsons, J.G. Gomez, E. Videa, J.P. Troiani, H.E. Santiago, P. 2002. Formation

and growth of Au nanoparticles inside live Alfalfa plants. Nano Lett., 2: 397-401.

Tripathy, A. Raichur, A.M. Chandrasekaran, N. Prathna, T.C. Mukherjee, A. 2010. Process

variables in biomimetic synthesis of silver nanoparticles by aqueous extract of

Azadirachta indica (Neem) leave. J Nanopart Res., 12: 237-246.

Bibliography Tsuda, H. Ohshima, Y. Nomoto, H. 2004. Cancer prevention by natural compounds. Drug

Metab Pharmacokinet .,19: 245-263.

Umesono, K. Evans, R.M. 1989. Determinants of target gene specificity for steroid/thyroid

hormone receptors. Cell., 57: 1139–1146.

Uren, A.G. 2000. Survivin and the INCENP show similar cell-cycle localization and gene

knockout phenotype. Curr. Biology., 10: 1319-1328.

Vader, G. Kauw, J.J. Medema, R.H. Lens, S.M. 2006. Survivin mediates targeting of the

chromosomal passenger complex to the centromer and midbody. EMBO Rep., 7: 85-92.

Vagnarelli, P. Earnshaw, W.C. 2004. Chromosomal passenger: the four dimensional regulation

of mitotic events. Chromosoma., 113: 211-222.

Verma, A. Stellacci, F. 2010. Effect of Surface Properties on Nanoparticle-Cell Interactions.

Small., 6:12-22.

Verrijk, R. Smolders, I.J. Bosnie, N. Begg, A.C. 1992. Reduction of systemic exposure and

toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide. Cancer Res., 52:

6653–6656.

Vigneshwaran, N. Kathe, A.A. Varadarajan, P.V. 2007. Nachane RP, Balasubramanya RH.

Functional finishing of cotton fabrics using silver nanoparticles. J. Nanosci

Nanotechnol., 7:1893-1897.

Von Hoff, D.D. Layard, M.W. Basa, P. Davis Jr, H.L. Von Hoff, A.L. Rozencweig, M. 1979.

Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med., 9: 710–

717.

Vong, Q. P. Cao, K. Li, H. Y. Lglesia, P. A. Zheng. Y. 2005. Chromosome alignment and

segregation regulated by ubiquitination of survivin. Science., 310: 1499-1504.

Bibliography Wang D, Lippard S.J. 2005. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug.

Discov., 2005: 4: 307-320.

Wang, Z. Fukunda, S. Pelus, L.M. 2004. Survivin regulates the p53 tumor suppressor gene

family. Oncogene., 23: 8146-8153.

Wenzel, U. Kuntz, S. Brendel, M.D. Daniel, H. 2000. Dietary flavone is a potent apoptosis

inducer in human colon carcinoma cells. Cancer Research., 60: 3823-3831.

Whealey, S. Carvalho, P. Vagnarelli, P. Earnshaw, W. 2001. INCEP is required for proper

targeting of survivin to the centromeres and proper anaphase spindle during mitosis. Curr

Bio., 11: 886-890.

Wheatly, P. Meneish, A. 2005. Survivin: A protein with dual role in mitosis and apoptosis.

International Review of cytology: 247.

Wimmershioff, J. Polkinghorne, A. Grest, P. Schade, B. Marchal, T. Keller, S.M. Guscetti, F.

2010. Immunohistochemical detection of survivin in canine lymphoma. J. Comp. Path.,

1-12.

Wu, J. Akaike, T. Hayashida, K. Okamoto, T. Okuyama, A. Maeda, H. 2001. Enhanced

vascular permeability in solid tumor involving peroxynitrite and matrix metallo

proteinases. Jpn. J. Cancer Res., 92: 439–451.

Wu, W. Wieckowski, S. Pastorin, G. Benincasa, M. Klumpp, C. Briand, J.P. Gennaro, R.

Prato, M. Bianco, A. 2005. Targeted delivery of amphotericin B to cells by using

functionalized carbon nanotubes. Angew. Chem., Int. Ed., 44: 6358-6362.

Xia, W. Low, P.S. 2010. Folate-targeted therapies for cancer. J. Med. Chem., 53: 6811–6824.

Bibliography Xu, J. Ma, L. Liu, Y. Xu, F. Nie, J. Ma, G. 2012. Design and characterization of antitumor

drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions. Int J Biol Macromol.,

50 : 438-443.

Xu, P.S. Van Kirk, E.A. Zhan, Y.H. Murdoch, W.J. Radosz, M. Shen, Y.Q. 2007. Targeted

charge-reversal nanoparticles for nuclear drug delivery. Angew. Chem., Int. Ed., 46:

4999-5002.

Xu, X.Y. Yang, Q.B. Bai, J. Lu, T.C. Li, Y.X. Jing, X.B. 2008. Fabrication of biodegradable

electrospun poly(L-lactide-co-glycolide) fibers with antimicrobial nanosilver particles. J

Nanosci Nanotechnol., 8: 5066-5070.

Xu, Y.M. Du, Y.M. 2003. Effect of molecular structure of chitosan on protein delivery properties

of chitosan nanoparticles. Int J Pharm .,250: 215-226.

Yan, F. Xu, H. Anker, J. Kopelman, R. Ross, B. Rehemtulla, A. 2004. Synthesis and

characterization of silica-embedded iron oxide nanoparticles for magnetic resonance

imaging. J. Nanosci. Nano-technol., 4: 72–76.

Yang, C.J. Wang, C.S. Hung, J.Y. Huang, H.W. Chia, Y.C. Weng, P.C. Huang, M.S. 2009.

Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in

an animal model. Lung Cancer., 66: 162–168.

Yang, X. Wang, H. Beasley, D.W. Volk, D.E. Zhao, X. Luxon B.A. 2006. Selection of

thioaptamers for diagnostics and therapeutics. Ann. N. Y. Acad. Sci., 1082:116-119.

Yang, X. 2000. Transcriptional activation of estrogen receptor alpha in human breast cancer cells

by histone deacetylase inhibition. Cancer Res., 60: 6890–6894.

Yarden, Y. Sliwkowski, M.X. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol.

Cell Biol., 2: 127–137.

Bibliography Yezhelyev, M.V. Gao, X. Xing, Y. Hajj, A.A. Nie, S. O’Regan, R.M. 2006. Emerging use of

nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol., 7: 657-667.

Yin, B. Ma, H. Wang, S. Chen, S. 2003. Electrochemical synthesis of silver nanoparticles under

protection of poly(N-vinylpyrrolidone). J Phys Chem B., 107: 8898-904.

Yong, K.T. Qian, J. Roy, I. Lee, H.H. Bergey, E.J. Tramposch K.M. 2007. Quantum rod

bioconjugates as targeted probes for Confocal and two-photon fluorescence imaging of

cancer cells. Nano Lett., 7: 761–765.

Youle, R.J. Strasser, A. 2008. The BCL-2 protein family: opposing activities that mediate cell

death. Nat.Rev.Mol Cell Biol., 9: 47-59.

Yu, S.W. Wang, H. Dawson, T.M. Dawson, V.L. 2003. Poly (ADP-ribose) polymerase-1 and

apoptosis inducing factor in neurotoxicity. Neurobiology of Disease., 14: 303-317.

Yuan, F. Dellian, M. Fukumura, D. Leunig, M. Berk, D.A. Torchilin, V.P. Jain, R.K. 1995.

Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff

size. Cancer Res., 553:752–756.

Zaffaroni, N. Pennati, M. Colella, G. 2002. Expression of the anti-apoptotic gene survivin

correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci., 59: 1406-

1412.

Zeiger, E.1998. Pyrogallol-review of toxicological literature. North Carolina: National Institute

of Environmental Health Sciences., 87: 66-71.

Zhang, M. Mukherjee, N. Bermudez, R.S. 2005. Adenovirus-mediated inhibition of survivin

expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.

Prostate: 64: 293-302.

Bibliography Zhang, Y.J. Nagao, T. Tanaka, T. Yang, C.R. Okabe, H. Kouno, I. 2004. Antiproliferative

activity of the main constituents from Phyllanthus emblica. Biol Pharm Bull.,

27(2):251–255.

Zhu, Z. Yuan, Li. Xiaolin Li. Rutian Li. Zhijun Jia. Baorui Liu. Wanhua Guo. Wei Wu. Xiqun

Jiang. 2010. Paclitaxel-loaded poly( N-vinylpyrrolidone)- b-poly(ε-caprolactone)

nanoparticles: Preparation and antitumor activity in vivo. Journal of Controlled

Release., 142 : 438-446.